Abstract
Leishmaniasis, a complex disease caused by at least 20 species of unicellular parasites of the genus Leishmania, disproportionately affects impoverished regions of about 90 tropical and sub-tropical countries. Currently available antileishmanial therapies, particularly for visceral leishmaniasis, are severely limited, with treatment outcome depending on many factors, including the immune status of the patient, comorbidities, malnutrition, and socio-economic conditions in the patient’s geographic location. There is an urgent need for new therapeutics, particularly new effective oral drugs, for visceral leishmaniasis. Despite the availability of the Leishmania genome sequence information and significant research into the biology of the parasites, antileishmanial drug development is hampered by the lack of knowledge about druggable targets in the parasite and difficulties in identifying the molecular targets of compounds that show activity. In this context, we analyzed recent progress in antileishmanial drug development programs, which take advantage of different powerful approaches, such as high-throughput screening of compound libraries, recent developments in genetic methods for assessing essentiality of parasite genes, and chemical, genetic, and proteomics-based target discovery and target validation methods.
Keywords: Leishmaniasis, phenotypic screening, target-based screening, CRISP/Cas9, cosmid library, proteasome, N-myristoylation, cyclin-dependent kinase.
Current Medicinal Chemistry
Title:Antileishmanial Drug Development: A Review of Modern Molecular Chemical Tools and Research Strategies
Volume: 28 Issue: 31
Author(s): Pavan K. Mantravadi, Anutthaman Parthasarathy and Karunakaran Kalesh*
Affiliation:
- Department of Chemistry, Durham University, Lower Mount Joy, South Road, Durham DH1 3LE,United Kingdom
Keywords: Leishmaniasis, phenotypic screening, target-based screening, CRISP/Cas9, cosmid library, proteasome, N-myristoylation, cyclin-dependent kinase.
Abstract: Leishmaniasis, a complex disease caused by at least 20 species of unicellular parasites of the genus Leishmania, disproportionately affects impoverished regions of about 90 tropical and sub-tropical countries. Currently available antileishmanial therapies, particularly for visceral leishmaniasis, are severely limited, with treatment outcome depending on many factors, including the immune status of the patient, comorbidities, malnutrition, and socio-economic conditions in the patient’s geographic location. There is an urgent need for new therapeutics, particularly new effective oral drugs, for visceral leishmaniasis. Despite the availability of the Leishmania genome sequence information and significant research into the biology of the parasites, antileishmanial drug development is hampered by the lack of knowledge about druggable targets in the parasite and difficulties in identifying the molecular targets of compounds that show activity. In this context, we analyzed recent progress in antileishmanial drug development programs, which take advantage of different powerful approaches, such as high-throughput screening of compound libraries, recent developments in genetic methods for assessing essentiality of parasite genes, and chemical, genetic, and proteomics-based target discovery and target validation methods.
Export Options
About this article
Cite this article as:
Mantravadi K. Pavan, Parthasarathy Anutthaman and Kalesh Karunakaran *, Antileishmanial Drug Development: A Review of Modern Molecular Chemical Tools and Research Strategies, Current Medicinal Chemistry 2021; 28 (31) . https://dx.doi.org/10.2174/0929867328666201125121018
DOI https://dx.doi.org/10.2174/0929867328666201125121018 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selective α7 Nicotinic Acetylcholine Receptor Ligands
Current Medicinal Chemistry Synthesis and Cytotoxicity Studies of New Morpholino-Functionalised and N-Heteroaryl-Substituted Titanocene Anticancer Drugs
Medicinal Chemistry Analytical Methods for the Quantification of Cisplatin, Carboplatin, and Oxaliplatin in Various Matrices over the Last Two Decades
Current Pharmaceutical Analysis Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry New Fabrication and Applications of Carbohydrate Arrays
Current Medicinal Chemistry Organocatalyzed Green Synthesis of 2,3-dihydropyrazines en Route to Medicinally Privileged Novel Polyheterocyclic Systems
Current Organocatalysis Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs
Current Medicinal Chemistry Non-Analgesic Effects of Opioids: Opioids’ Effects on Sleep (Including Sleep Apnea)
Current Pharmaceutical Design Emerging Toxicity Aspects of Silver Nanoparticles: An Overview
Current Nanomaterials Medical-surgical Combined Approach in Perianal Fistulizing Crohn's Disease (CD): Doing it Together
Current Drug Targets Advances and Perspectives in Cell-Specific Aptamers
Current Pharmaceutical Design Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective
Current Drug Targets Manipulating the Ability of Substituted Titanocene Derivatives to Induce Apoptosis in Castrate-Resistant Prostate Cancer Cells
Letters in Drug Design & Discovery Beneficial and Detrimental Effects of Antioxidants Use in Sports: How is it Balanced?
Current Nutraceuticals Asafoetida, Natural Medicine for Future
Current Nutrition & Food Science Sugars and Sweeteners: Structure, Properties and In Silico Modeling
Current Medicinal Chemistry Applications of Metabonomics in Pesticide Toxicology
Current Drug Metabolism Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Extraction Methods for Downstream Processing of Bioactive Compounds From Natural Sources
Current Biochemical Engineering (Discontinued)